Studies on some glitazones having pyridine as the linker unit

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 4, 2004, Pages 655-662

  Ramachandran, Uma ^a   Mital, Alka ^a   Bharatam, Prasad V ^a   Khanna, Smriti ^a   Rao, Poduri Rama ^a   Srinivasan, Krishnamoorthy ^a   Kumar, Rakesh ^a   Singh Chawla, Harmander Pal ^a   Kaul, Chaman Lal ^a   Raichur, Suryaprakash ^b   Chakrabarti, Ranjan ^b  

^a SAS Nagar   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

AM1 calculations; Conformational rigidity; PPARg agonists; Pyridine analogues of TZDs; Transactivitaion; Type 2 diabetes

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PYRIDINE DERIVATIVE;

ARTICLE; DRUG CONFORMATION; DRUG EFFICACY; DRUG SYNTHESIS; EVALUATION; MATHEMATICAL COMPUTING; MOLECULAR MODEL;

EID: 0842305208     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2003.11.027     Document Type: Article

References (33)

1. Amos A.F., McCarty D.J., Zimmet P. Diabetic Med. 14:1997;S1.
2. Zimmet P., McCarty D. J. IDF Bulletin. 40:1995;8.
3. King H., Albert R.E., Herman W.H. Diabetes Care. 21:1998;1414.
4. De Fronzo R.A. Diabetes. 37:1988;667.
5. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., Kliwer S.A. J. Biol. Chem. 270:1995;12953.
6. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lehman J.M. J. Med. Chem. 39:1996;665.
7. Pershadsingh H.A. Exp. Opin. Invest. Drugs. 8:1999;1.
8. Jones A.B. Med. Res. Rev. 21:2001;540.
9. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. J. Med. Chem. 43:2000;527.
10. Sohda T., Mizuno K., Imamiya E., Sugiyama Y., Fujita T., Kawamatsu Y. Chem. Pharm. Bull. 30:1982;3580.
11. Fujita T., Sugiyama Y., Taketomi S., Sohda T., Kawamatsu Y., Iwatsuka H., Suzuoki Z. Diabetes. 32:1983;804.
12. Wagman A.S., Nuss J.M. Curr. Pharm. Des. 7:2001;417.
13. Rami H.K., Smith S. A. Exp. Opin. Ther. Patents. 10:2000;623.
14. Chen H.C., Smith S.J., Ladha Z., Jensen D.R., Ferreira L.D., Pulawa L.K., McGuire J.G., Pitas R.E., Eckel R.H., Farese R.V. J. Clin. Invest. 109:2002;1049.
15. Hulin B., Clark D.A., Goldstein S.W., McDermott R.E., Dambek P.J., Kappeler W.H., Lamphere C.H., Lewis D.M., Rizzi J.P. J. Med. Chem. 35:1992;1853.
16. Zask A., Jirkovsky I., Nowicki J.W., McCaleb M.L. J. Med. Chem. 33:1990;1418.
17. Hulin B., Newton L.S., Lewis D.M., Genereux P.E., Gibbs E.M., Clark D.A. J. Med. Chem. 39:1996;3897.
18. Arakawa K., Inamasu M., Matsumoto M. Chem. Pharm. Bull. 45:1997;1984.
19. Sohda, T.; Ikeda, H.; Imai, S.; Momose, Y. EP 0605228A1, 1994.
20. Momose Y., Maekawa T., Yamano T., Kawada M., Odaka H., Ikeda H., Sohda T. J. Med. Chem. 45:2002;1518.
21. Tetsuya, K.; Takashi, Y.; Takeshi, N.; Suke, O. K.; Katsuhiro, K.; Yoshio, O.; Mikio, S.; Nobuhide, M.; Chi, S. K. WO 9526347, 1995.
22. Kulkarni S.S., Gediya L.K., Kulkarni V.M. Bioorg. Med. Chem. 7:1999;1475.
23. Momose Y., Maekawa T., Odaka H., Ikeda H., Sohda T. Chem. Pharm. Bull. 50:2002;100.
24. Dewar M.J.S., Zoebisch E.G., Healy E.F., Stewart J.J.P. J. Am. Chem. Soc. 107:1985;3902.
25. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Nature. 395:1998;137.
26. Iwata Y., Miyamoto S., Takamura M., Yanagisawa H., Kasuya A. J. Mol. Graphics Modell. 19:2001;536.
27. Ebdrup S., Pettersson I., Rasmussen H.B., Deussen H.J., Jensen A.F., Mortensen S.B., Fleckner J., Pridal L., Nygaard L., Sauerberg P. J. Med. Chem. 46:2003;1306.
28. Hehre W.J., Radom L., Schleyer P.v.R., Pople J.A. Ab initio Molecular Orbital Theory. 1986;Wiley, New York.
29. Wong M.W., Wiberg K.B., Frisch M.J. J. Chem. Phys. 95:1999;8991.
30. Karlin K.D., Nasir M.S., Cohen B.I., Cruse R.W., Kaderli S., Zuberbuhler A.D. J. Am. Chem. Soc. 116:1994;1324.
31. Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., Gershome C., Suresh J., Rajagopalan R. Br. J. Pharmacol. 140:2003;527.
32. Rao, P. R. et al; unpublished results. In vivo tests of compound 4 conducted in HFD rats showed it to be significantly active towards oral glucose tolerance, triglyceride lowering capacity and insulin sensitivity.
33. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Zakrzewski V.G., Montgomery J.A., Stratmann R.E. Jr., Burant J.C., Dapprich S., Millam J.M., Daniels A.D., Kudin K.N., Strain M.C., Farkas O., Tomasi J., Barone V., Cossi M., Cammi R., Mennucci B., Pomelli C., Adamo C., Clifford S., Ochterski J., Petersson G.A., Ayala P.Y., Cui Q., Morokuma K., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Cioslowski J., Ortiz J.V., Baboul A.G., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Gomperts R., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Gonzalez C., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Andres J.L., Gonzalez C., Head-Gordon M., Replogle E.S., Pople J.A. Gaussian 98. 1998;Gaussian Inc, Pittsburgh PA.